Precipio, Inc. filings document the public-company disclosures of a specialty cancer diagnostics issuer with Pathology Services and Products operations. Its Form 8-K reports include Regulation FD updates for shareholder calls and investor presentations, furnished financial results, and material-event disclosures related to corporate communications and operating performance.
The company’s proxy materials describe annual meeting procedures, stockholder voting matters, governance, and access to annual reporting materials. Other filings document capital-structure matters, including common stock activity and the termination of an at-the-market sales agreement, alongside formal exhibits and disclosures tied to Precipio’s diagnostics business and shareholder communications.
Precipio, Inc. Chief Operating Officer Sabet Ahmed Zaki reported two transactions dated 01/02/2026. He was granted a stock option for 15,000 shares of common stock with an exercise price of $23.82 per share, issued under the company’s Equity Incentive Plan for his service as an officer. These options will vest and become exercisable only if the 10-day volume-weighted average price of Precipio’s common stock exceeds $40 per share. He also purchased 20 shares of common stock at $23.40 per share under a Rule 10b5-1 trading plan, increasing his directly held common stock to 735 shares.
Precipio, Inc. reported a routine insider equity grant to director Kathleen LaPorte. On 01/02/2026, she was awarded a stock option for 1,500 shares of common stock at an exercise price of $23.82 per share, granted under the company’s Equity Incentive Plan in consideration for her board service.
The options vest in twelve equal monthly installments beginning one month after the grant date and are exercisable until 01/02/2036. Following this grant, LaPorte beneficially owns 1,500 derivative securities as a director with direct ownership.
Precipio, Inc. reported a new stock option grant to its Chief Financial Officer, Gage Matthew, in a Form 4 filing. On 01/02/2026, he was awarded 5,000 stock options classified as a derivative security. The award was granted as consideration for his service as an officer under the company’s Equity Incentive Plan.
The options have an exercise price of $23.82 per share and vest only when the 10-day volume-weighted average price (VWAP) of Precipio’s common stock exceeds $40 per share. Following this grant, he beneficially owns 5,000 stock options directly.
Precipio, Inc. reported that its Chief Executive Officer and director, Danieli Ilan, received a grant of stock options on January 2, 2026. The award covers 15,000 stock options, each giving the right to buy one share of Precipio common stock at an exercise price of $23.82 per share, and is granted under the company’s Equity Incentive Plan as consideration for his service.
According to the terms, these options vest and become exercisable only when the 10-day volume-weighted average price (VWAP) of Precipio’s common stock exceeds $40 per share. The options have an expiration date of January 2, 2036, and following this grant, Ilan directly holds 15,000 derivative securities in the form of these stock options.
Precipio, Inc. director Jeffrey Cossman received a grant of stock options for 1,500 shares of common stock. The options were awarded on 01/02/2026 under the company’s Equity Incentive Plan in consideration for his service as a director and carry an exercise price of $23.82 per share.
The options vest in twelve equal monthly installments beginning one month after the grant date and are exercisable through 01/02/2036. Following this grant, Cossman holds 1,500 derivative securities directly.
Precipio, Inc. reported an insider equity award to director Cohen David Seth. On January 2, 2026, he received a grant of 1,500 stock options, described as a stock option (right to buy) common stock, at an exercise price of $23.82 per share. The award was granted under the company’s equity incentive plan as consideration for his service as a director and was recorded as acquired at no cost on the grant date. Following this grant, he beneficially owns 1,500 derivative securities directly. The options vest in twelve equal monthly installments beginning one month after the grant date and expire on January 2, 2036.
Precipio, Inc. director Ronald Andrews received a grant of 1,500 stock options on January 2, 2026. These options give him the right to buy 1,500 shares of common stock at an exercise price of $23.82 per share and expire on January 2, 2036. The options were granted under the company’s equity incentive plan as consideration for his service as a director. They vest in twelve equal monthly installments beginning on the one-month anniversary of the grant date, and he beneficially owns 1,500 derivative securities directly following this grant.
Precipio, Inc. insider activity: the company’s Chief Operating Officer, Ahmed Zaki Sabet, reported a small open-market purchase of common stock. On 10/01/2025, he acquired 25 shares of Precipio common stock at a price of $19.50 per share, in a transaction coded as a purchase. Following this transaction, he beneficially owns 715 shares of Precipio common stock in direct ownership form. The filing notes that these shares are being purchased pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Precipio, Inc. (PRPO) reported an insider stock purchase by its Chief Operating Officer. On 07/08/2025, the COO acquired 31 shares of common stock in an open-market transaction at $16.3 per share, increasing the directly held position to 690 shares. The filing notes that these shares are being purchased under a pre-established Rule 10b5-1 trading plan adopted by the reporting person, which is designed to provide an affirmative defense against insider trading claims when trading while in possession of material nonpublic information.
Precipio, Inc. (PRPO) reported Q3 2025 results. Net sales were $6,767 thousand, up from $5,209 thousand a year ago, driven by higher diagnostic testing revenue from Medicare and third-party payers. Gross profit rose to $3,005 thousand. Operating loss narrowed to $61 thousand and net loss improved to $79 thousand from $626 thousand.
For the nine months, net sales were $17,350 thousand versus $13,082 thousand, with net loss improving to $889 thousand from $3,925 thousand. Cash at quarter-end was $2,305 thousand, aided by $1,260 thousand of warrant exercise proceeds and $319 thousand provided by operating activities. The company disclosed “substantial doubt” about its ability to continue as a going concern over the next twelve months. As of November 11, 2025, common shares outstanding were 1,752,007.